Biotech News

GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update

GH Research (GHRS)GH ResearchEarnings

Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visit TRD pivotal program — positive initial feedback from FDA, End-of-Phase 2 meeting expected in Q1 2027, initiation shortly after PPD pivotal program —

Related news

GH Research

Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders. GH001 GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals...

Recent company news

Stock data

Close
18.56 USD
Market cap
1.71B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States